CClinicalTrials.gg
CompletedNCT03712891Updated Dec 13, 2024Results posted

Evaluation of Providing Coffee to Patients Postoperatively to Decrease Length of Stay in the PACU

An interventional study of Coffee in PACU Length of Stay, Postoperative Nausea and Postoperative Vomiting, sponsored by TriHealth Inc.. Completed at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-12-13.

Sponsored by TriHealth Inc. · Not applicable, Interventional, and Health services research

Phase
Not applicable
Study type
Interventional
Enrollment
178
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of the study is to determine if providing coffee to patients who self-identify as coffee drinkers postoperatively will decrease the length of stay in the post-anesthesia care unit (PACU).

Read the detailed description

Decreasing the length of stay in PACU for surgical patient is a pertinent outcome. The shorter length of stay can achieve higher patient engagement scores, while simultaneously increasing the productivity of the unit. This is achieved by making more beds available for new patients coming from the operating room (OR). One thought was that coffee would benefit the investigator's patients experience through a number of pathways. Initially, the stimulant effect of coffee would create a more alert patient. A more alert patient is more likely to comprehend home care instruction and be ready for discharge earlier. Coffee is often used as a remedy for morning sickness. Ideally the act of drinking coffee or even smelling the coffee may decrease the occurrence of Post-Operative Nausea and Vomiting (PONV) in investigator's patient population. Finally, patients frequently state that the inability to drink their morning coffee is often more difficult than not being able to eat prior to surgery. By allowing those to drink coffee in PACU this would make the patient feel that they are being cared for on an emotional level, in addition to a physical level.

02

Conditions studied

  • PACU Length of Stay
  • Postoperative Nausea
  • Postoperative Vomiting
  • Patient Satisfaction

Keywords

  • PACU length of stay
  • coffee
03

In context

Vomiting

1,100 studies on the registry are indexed under Vomiting; 134 are open to participants now.

This study's enrollment of 178 is above the median of 107 across 935 interventional studies indexed under Vomiting.

Browse Vomiting studies →

Lead sponsor

TriHealth Inc. is the lead sponsor of 99 studies on the registry; 9 are open to participants now.

Of its 9 completed or terminated interventional studies of FDA-regulated products, 4 (44%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  1. 18 years old or older
  2. Admitted to Bethesda North Minimally Invasive Surgery Center
  3. Reports to consume at least one cup of coffee a day for at least 5 days in a week

Exclusion criteria

Exclusion Criteria

  1. History of PONV
  2. Pre-existing cardiac arrhythmias
  3. History of seizure disorder
  4. Pregnant
05

Study design

Phase
Not applicable
Primary purpose
Health services research
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
178 participants (actual)

Study arms

  • Experimental
    Patients receiving coffee postoperatively

    Patients who self-identify as coffee drinkers and receive coffee postoperatively

    Dietary Supplement: Coffee

  • No intervention
    Patients not receiving coffee postoperatively

    Patients who self-identify as coffee drinkers and do not receive coffee postoperatively

Interventions

  • Dietary supplementCoffee

    Patients will receive coffee in a Styrofoam cup at a temperature of 125 degree Fahrenheit or less. Coffee will be offered to the patient in the PACU once the patient's gag reflex has been restored following their procedure. Volume of estimated coffee consumption will be measured using a sample scale (with a maximum of 300mL of coffee offered)

06

What researchers measure

Primary outcomes

  1. PACU Length of Stay

    Post-anesthesia Care Unit length of stay

    Time frame: 6 hours

07

Results

Posted Dec 13, 2024

Participant flow

Participant flow — Overall Study
MilestonePatients Receiving Coffee PostoperativelyPatients Not Receiving Coffee Postoperatively
Started8989
Completed8989
Not completed00

Outcome measures

PrimaryPACU Length of Stay

Post-anesthesia Care Unit length of stay

Time frame:
6 hours
Reported as:
Mean · minutes
PACU Length of Stay
minutesPatients Receiving Coffee PostoperativelyPatients Not Receiving Coffee Postoperatively
PACU Length of Stay82 ± 5.1376 ± 5.13
Statistical analysis
  • Patients Receiving Coffee Postoperatively · t-test, 2 sided · p = 0.12

Adverse events

Collected over Patient level: Less than 6 hours Study level: During length of study. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Patients Receiving Coffee Postoperatively0/89 (0%)0/89 (0%)0/89 (0%)
Patients Not Receiving Coffee Postoperatively0/89 (0%)0/89 (0%)0/89 (0%)

Baseline characteristics

Age, Customized
Age, Customized(Participants)Patients Receiving Coffee PostoperativelyPatients Not Receiving Coffee PostoperativelyTotal
18 years or older8989178
Sex/Gender, Customized
Sex/Gender, Customized(Participants)Patients Receiving Coffee PostoperativelyPatients Not Receiving Coffee PostoperativelyTotal
Did not collect000
Race and Ethnicity Not Collected
Race and Ethnicity Not Collected(Participants)Patients Receiving Coffee PostoperativelyPatients Not Receiving Coffee PostoperativelyTotal
Count of participants——0
Region of Enrollment
Region of Enrollment(participants)Patients Receiving Coffee PostoperativelyPatients Not Receiving Coffee PostoperativelyTotal
United States8989178
08

Study locations

1 site
  • Bethesda North Hospital
    Cincinnati, Ohio 45242, United States
09

References and documents

Study documents

  • Protocol and statistical analysis plan · Apr 6, 2022

Documents are hosted by the registry — open the source record to download them.

Individual participant data

Plan to share: No

10

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Dec 13, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03712891
Lead sponsor
TriHealth Inc.
Responsible party
Rachel Baker (Nurse Researcher, TriHealth Inc.) — Principal investigator
First posted
Oct 19, 2018
Start date
Oct 25, 2018
Primary completion
Jul 1, 2023
Completion
Aug 16, 2023
Results posted
Dec 13, 2024
Last update
Dec 13, 2024

Study contacts

Brandon Ballhaus, BSN, RN
principal investigator · TriHealth Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion